MDNA56 and MDNA57 are our next generation IL-4 Empowered Cytokines™ (IL4-ECs) carrying a fully human cell killing payload. Whereas MDNA55 has the ability to efficiently target both, Type 1 and Type 2 IL-4R, MDNA56 and MDNA57 have specific bias towards either, the Type 1 or Type 2 IL-4R, respectively.

The IL-4 Superkine™ used to generate MDNA56 has an affinity for the Type 1 IL-4R which is 7000-fold higher then that of MDNA57. On the other hand, MDNA57 has an affinity for Type 2 IL-4R that is 2000-fold greater then that of MDNA56. Each of these IL4-ECs therefore provide a higher degree of selectivity for their intended use and are engineered to have a much better safety and efficacy profile.

MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.